Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 5 30 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 5 30 versus TAYTULLA.
AUROVELA FE 1.5/30 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet orally once daily at the same time each day for 28 consecutive days.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethindrone: 5-14 hours (terminal); Ethinyl estradiol: 10-20 hours (terminal). Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal: ~50-60% as metabolites, <10% unchanged; Fecal: ~40-50% via bile; Ethinyl estradiol undergoes enterohepatic recirculation.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive